Saturday 17 October 2026
Export PTGX’s income statement to Excel — free account
Protagonist Therapeutics, Inc.
PTGX Healthcare Biotechnology
Protagonist Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $46.0 million, down 89.4% from fiscal 2024. In the quarter to June 2026, revenue grew 3,749.2%, EPS grew 549.1% and free cash flow grew 839.7%, each against the same quarter a year earlier.
128.75
7.80
−5.71%
Follow PTGX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
100.48 | 0.00 | 0.00 | 88.57 |
+8 more quarters Free account |
P/S ratio |
28.66 | 92.63 | 120.66 | 20.25 | |
P/FCF ratio |
61.90 | 0.00 | 99.01 | 66.49 | |
P/Operating CF |
36.90 | (140.17) | (150.17) | (2,187.08) | |
P/B ratio |
9.60 | 10.47 | 9.03 | 6.56 | |
Price to Tangible BV |
9.60 | 10.47 | 9.03 | 6.56 | |
EV/Sales |
25.92 | 85.36 | 108.55 | 17.54 | |
EV/EBITDA |
129.65 | 0.00 | 0.00 | 281.36 | |
EV/Operating CF |
55.72 | (54.21) | 86.61 | 56.06 | |
EV/FCF |
55.98 | (53.63) | 89.07 | 57.60 | |
Quick Ratio |
21.41 | 17.41 | 12.49 | 12.83 | |
Current Ratio |
21.71 | 17.76 | 12.71 | 13.05 | |
Net Debt/EBITDA |
(4.96) | 143.14 | 11.13 | 12.39 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.35 | 0.10 | 0.07 | 0.32 | |
Operating CF/Net income |
1.35 | (12.94) | 0.83 | 0.05 | |
Capex/Depreciation |
0.15 | 1.20 | 0.23 | 1.10 | |
Research and Development Expense of Revenue |
19.70% | 82.92% | 623.34% | 848.96% | |
Selling, General and Administrative Expense of Revenue |
5.92% | 23.55% | 153.74% | 236.21% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
6.58% | 25.76% | 143.89% | 224.09% | |
Graham Net Nets |
0.09 | 0.08 | 0.09 | 0.13 | |
Graham Number |
18.72 | 0.00 | 0.00 | 13.07 | |
Earnings Yield |
1.00% | (1.71%) | (2.35%) | 1.13% | |
Free Cash Flow Yield |
1.62% | (1.72%) | 1.01% | 1.50% | |
Revenue per Share |
3.24 | 0.87 | 0.12 | 0.07 | |
Operating CF per Share |
3.32 | (0.75) | (0.58) | (0.03) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
3.32 | (0.76) | (0.58) | (0.03) | |
Cash per Share |
11.87 | 8.42 | 8.92 | 9.03 | |
Shareholders Equity per Share |
12.76 | 10.07 | 9.67 | 10.12 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
12.76 | 10.07 | 9.67 | 10.12 | |
Free Cash Flow |
218.88 | (49.16) | (37.12) | (2.02) | |
Working Capital |
769.97 | 578.91 | 532.13 | 541.48 | |
Capital Expenditures |
(0.17) | (0.21) | (0.14) | (0.09) | |
Net Current Asset Value |
763.15 | 571.47 | 524.09 | 530.17 | |
EV/EBIT |
125.29 | 0.00 | 0.00 | 193.08 | |
Capex to Sales |
0.00 | 0.00 | 0.02 | 0.02 | |
Price to Operating Income |
138.54 | 0.00 | 0.00 | 222.87 | |
| Other line items | |||||
Average Receivables |
89.21 | 26.85 | 150.08 | 5.29 | |
Average Payables |
3.35 | 5.68 | 3.48 | 4.35 | |
Average Assets |
801.78 | 719.80 | 706.46 | 652.77 | |
Average Common Equity |
754.78 | 672.26 | 645.00 | 588.68 |
Columns are period end dates